Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review

Int Immunopharmacol. 2021 Apr 21;97:107707. doi: 10.1016/j.intimp.2021.107707. Online ahead of print.ABSTRACTSince late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, better known as COVID-19) has rapidly spread worldwide. The primary pathophysiology by which COVID-19 leads to severe lung damage is cytokine releasing syndrome (CRS), which can cause death. Therefore, removing cytokines via therapeutic plasma exchange or hemoperfusion could be a therapeutic approach to treat CRS. However, hemoperfusion or therapeutic plasma exchange could alter the effectiveness of concomitant medications. Thus, concomitant medication doses might need to be adjusted to prevent their elimination via therapeutic plasma exchange or hemoperfusion, thus ensuring that these medications remain effective. This narrative review investigates the elimination status of current medications used to manage COVID-19 during hemoperfusion and therapeutic plasma exchange, with a focus on their pharmacokinetic profiles.PMID:33962224 | PMC:PMC8059942 | DOI:10.1016/j.intimp.2021.107707

Source: International Immunopharmacology - May 7, 2021 Category: Allergy & Immunology Authors: Shervin Shokouhi Saghar Barati Neda Kazeminia Faezeh Jamali Baran Roshan Zahra Sahraei Source Type: research